Upadacitinib Outperforms Other Advanced Therapies After TNF Inhibitor Failure in Registry Data
This sponsor-funded registry analysis offers adjusted real-world comparative response data for upadacitinib after tumor necrosis factor inhibitor (TNFi) exposure, but sample size, data imputation, and absent safety data limit how far pharmacists can act on it.
📅 Journal publication: Nov 3, 2026·Last updated: Nov 6, 2026
Upadacitinib outperforms other advanced therapies in RA remission rates.
This study guides treatment decisions for rheumatoid arthritis (RA) patients with inadequate response to tumor necrosis factor inhibitors (TNFi). 43.8% of patients on upadacitinib achieved low disease activity/remission at 12 months, compared to 23.4%-31.5% on other advanced therapies. The study provides real-world evidence favoring upadacitinib over other therapies in achieving clinical goals in RA patients post-TNFi failure. Upadacitinib may be more effective than other therapies in achieving remission in RA after TNFi use.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Charles-Schoeman C, Oelke K, Saffore CD, Kadakia A, Peng Y, Fang S, Markley G, Bergman MJ
Citation:Charles-Schoeman C, Oelke K, Saffore CD, et al. Effectiveness of Upadacitinib Versus Other Advanced Therapies in Rheumatoid Arthritis After Tumor Necrosis Factor Inhibitor Use in the United States. Rheumatology and therapy. 2026. doi:10.1007/s40744-026-00885-8